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Radiation-induced sarcomas (RIS) represent rare 
complications of radiation therapy but their prog-
nosis is poor. The consensual definition was first 
proposed by Cahan in 1948 [1] based on prior his-
tory of radiation therapy and occurrence of a his-
tologically-proven sarcoma within the irradiation 
fields after a latency period longer than five years. 
The pleura is made of tissues of diverse histologi-
cal origin (mesothelium and connective tissues, 
such as blood or lymphatic vessels) explaining the 
diversity of radiation-induced pleural side-effects, 
such as effusion, thickening or mesothelioma. Yet, 
pleural RIS have never been evaluated in epidemio-
logical studies. We aimed to better understand the 
characteristics of pleural RIS based on the SEER 
Program cancer registry.
Seer registry analysis 
Pleural sarcomas were identified in the SEER 
18-registry database (1973–2015), using the 
SEER*STAT software (version 8.3.6) for data ex-
traction. Identification was based on biopsy-prov-
en sarcoma histology (classified as “IX Soft tissue 
and other extraosseous sarcomas”, according to the 
Classification for International Classification for 
Childhood Cancer Recode ICD-O-3/World Health 
Organization 2008), on pleural primary localiza-
tion (classified as “C-38.4-Pleura”, according to the 
International Classification of Diseases, 10th Revi-
sion, Clinical Modification (ICD-10-CM) classifica-
tion system) and on malignant behavior (excluding 
neoplasms of intermediate malignancy, according 
to the WHO classification, such as solitary fibrous 
tumors or histiocytomas). Among pleural sarco-
mas, we identified pleural RIS based on Cahan RIS 
definition (1):  
• there should be a prior history of cancer occur-
ring at least five years before pleural sarcoma 
occurrence;
• this previous cancer should have been treated 
with radiation therapy. This information was 
available in the SEER radiation/chemotherapy 
database;
• the pleura had to be included in the expected 
irradiation fields, as is the case for homolateral 
breast or lung cancers. 
Out of 8 million cancer patients from the 18-reg-
istry SEER database (1973–2015), 197 malignant 
pleural sarcoma patients were identified (0.0024%). 
Median age was 66 (3-91). There were 133 (67.5%) 
male and 64 (32.5%) female patients. The most fre-
quent specified histological types were angiosar-
comas (n = 27, 13.7%), synovial sarcomas (n = 24, 
12.2%), spindle cell sarcomas (n = 24, 12.2%) and 
fibrosarcomas (n = 13, 6.6%). 
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Of these 197 pleural sarcoma patients, three 
fulfilled criterions for pleural RIS (Tab. 1). Age 
at sarcoma diagnosis ranged between 54 and 74. 
All patients were women, previously irradiated 
for homolateral breast cancer. The median la-
tency period before sarcoma occurrence ranged 
between 14 and 20 years. Surgery was attempt-
ed for one patient. Median overall survival was 
4 months. 
discussion
Development of radiation-induced sarcoma oc-
curs in 0.03% to 0.2% of post-irradiation follow-up, 
over a 10-year period [2]. Pleural RIS are exceed-
ingly rare; in addition to the three patients identi-
fied in the SEER registry, only one other case has 
been described [3]: angiosarcoma developed four 
years after lung irradiation. Treatment may rely on 
surgery when possible and chemotherapy, but over-
all survival seems very poor.
All pleural RIS cases from the SEER database 
occurred after breast radiation therapy; this rare 
diagnosis should, therefore, be suspected in front 
of pleural effusion or mass years after homolateral 
breast radiation-therapy. However, in a cohort of 
16,000 breast cancer patients, Kirova et al. found 
that the most frequent RIS localization were the 
breast and the chest wall [4]. Interestingly, no pleu-
ral RIS were evidenced, despite frequent inclusion 
of anterior thoracic pleura into tangential radia-
tion fields. Tissue radiation sensitivity differences 
for sarcoma carcinogenesis could be hypothesized. 
Current state-of-the-art breast radiation therapy 
techniques, such as intensity modulated radiation 
therapy, tend to increase lung and pleura exposure 
compared with traditional irradiation approaches 
[5]. Long-term studies focusing on recent radiation 
therapy techniques will thus be needed to evaluate 
late pleuro-pulmonary toxicity.
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Table 1. Characteristics of pleural radiation-induced sarcomas from the Seer database (1973–2015)
Diagnosis 
year





right breast invasive 
carcinoma
16 years Fibrosarcoma No
died after  
18 months
2000 Female 74






died after  
1 month
2014 Female 84
left breast invasive 
carcinoma
20 years Synovial sarcoma No
died after  
4 months
